MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-02-2026
uniQure N.V. Total Assets 2011-2026 | QURE
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets uniQure N.V.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 825 M | 557 M | 832 M | 705 M | 809 M | 340 M | 449 M | 274 M | 210 M | 190 M | 265 M | 116 M | 53.8 M | 7.36 M | 7.52 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 832 M | 7.36 M | 376 M |
Quarterly Total Assets uniQure N.V.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 888 M | 585 M | 605 M | 557 M | 646 M | 731 M | 770 M | 832 M | 872 M | 943 M | 631 M | 705 M | 638 M | 701 M | 757 M | 809 M | 775 M | 784 M | 364 M | 340 M | 340 M | 340 M | 340 M | 449 M | 449 M | 449 M | 449 M | 274 M | 274 M | 274 M | 274 M | 210 M | 210 M | 210 M | 210 M | 190 M | 190 M | 190 M | 190 M | 263 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 943 M | 190 M | 493 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M |  Germany |
 |
Autolus Therapeutics plc
AUTL
|
589 M | $ 1.35 | -2.91 % | $ 359 M |  Britain |
 |
Coherus BioSciences
CHRS
|
258 M | $ 1.61 | -3.59 % | $ 189 M |  USA |
 |
I-Mab
IMAB
|
6.33 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
151 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M | France |
 |
Catalyst Pharmaceuticals
CPRX
|
1.1 B | $ 24.88 | -0.4 % | $ 3.04 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
168 M | $ 10.02 | -1.16 % | $ 133 M | USA |
 |
Midatech Pharma plc
MTP
|
14.8 M | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | USA |
 |
Cardiff Oncology
CRDF
|
61.9 M | $ 1.57 | -0.63 % | $ 105 M | USA |
 |
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K | USA |
 |
Alterity Therapeutics Limited
ATHE
|
41.4 M | $ 3.65 | 1.3 % | $ 8.78 B |  Australia |
 |
Advaxis
ADXS
|
16.6 M | - | -9.65 % | $ 45.9 M | USA |
 |
DBV Technologies S.A.
DBVT
|
234 M | $ 20.25 | -0.54 % | $ 2.83 B | France |
 |
Adverum Biotechnologies
ADVM
|
180 M | - | - | $ 86.2 M | USA |
 |
Aytu BioScience
AYTU
|
124 M | $ 2.55 | -4.14 % | $ 16 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - |  Russia |
 |
Dyadic International
DYAI
|
9.95 M | $ 0.87 | - | $ 31.5 M | USA |
 |
Aeterna Zentaris
AEZS
|
35.1 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
6.95 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
778 M | - | - | $ 1.01 B | USA |
 |
Entera Bio Ltd.
ENTX
|
10.3 M | $ 1.17 | -2.1 % | $ 64 M |  Israel |
 |
Equillium
EQ
|
31.9 M | $ 2.0 | -0.5 % | $ 115 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.7 M | - | - | $ 26.5 M | USA |
 |
Evogene Ltd.
EVGN
|
39.9 M | $ 0.8 | 2.49 % | $ 27.9 M | Israel |
 |
AIkido Pharma
AIKI
|
113 M | - | 1.93 % | $ 17.4 M | USA |
 |
Fate Therapeutics
FATE
|
319 M | $ 1.15 | -3.78 % | $ 137 M | USA |
 |
Forte Biosciences
FBRX
|
82.8 M | $ 26.15 | -1.1 % | $ 339 M | USA |
 |
Aptose Biosciences
APTO
|
10 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Fennec Pharmaceuticals
FENC
|
70.6 M | $ 6.2 | -3.43 % | $ 177 M | USA |
|
Foghorn Therapeutics
FHTX
|
198 M | $ 4.75 | -2.59 % | $ 299 M | USA |
 |
Amicus Therapeutics
FOLD
|
950 M | $ 14.46 | 0.03 % | $ 4.46 B | USA |
 |
Akero Therapeutics
AKRO
|
826 M | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
1.16 B | - | - | $ 867 M | Germany |
 |
BioNTech SE
BNTX
|
22 B | $ 88.37 | -3.19 % | $ 27.2 B | Germany |
 |
Akari Therapeutics, Plc
AKTX
|
47.9 M | $ 3.52 | -0.56 % | $ 237 B | Britain |
 |
Akouos
AKUS
|
279 M | - | 0.23 % | $ 488 M | USA |
 |
Fulcrum Therapeutics
FULC
|
366 M | $ 7.45 | -4.85 % | $ 472 K | USA |
 |
Galectin Therapeutics
GALT
|
19.5 M | $ 2.38 | -7.03 % | $ 152 M | USA |
 |
Allakos
ALLK
|
244 M | - | - | $ 28.6 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
34.8 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
4.97 B | $ 315.4 | -4.52 % | $ 41.3 B | USA |
 |
Alpine Immune Sciences
ALPN
|
287 M | - | - | $ 2.17 B | USA |
 |
Gilead Sciences
GILD
|
59 B | $ 138.37 | -1.26 % | $ 172 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
18.5 M | $ 0.54 | 4.26 % | $ 503 K | Israel |
 |
Aileron Therapeutics
ALRN
|
24.2 M | - | 10.36 % | $ 9.8 M | USA |
 |
Genmab A/S
GMAB
|
21.1 B | $ 27.13 | -2.25 % | $ 17 B |  Danmark |
 |
AlloVir
ALVR
|
122 M | - | 4.14 % | $ 49.1 M | USA |